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Abstract
Speciﬁc blue–yellow colour vision impairment has been reported in dependent cocaine users and it was
postulated that drug-induced changes in retinal dopamine neurotransmission are responsible. However,
it is unclear whether these changes are conﬁned to chronic cocaine users, whether they are speciﬁc for
dopaminergic stimulants such as cocaine and amphetamine and whether they are related to cognitive
functions such as working memory, encoding and consolidation. In 47 occasional and 29 dependent
cocaine users, 23 MDMA (commonly known as ‘ecstasy’) users and 47 stimulant-naive controls, colour
vision discrimination was measured with the Lanthony Desaturated Panel D-15 Test and memory
performance with the Auditory Verbal Learning Test. Both occasional and dependent cocaine users
showed higher colour confusion indices than controls. Users of the serotonergic stimulant MDMA (26%),
occasional (30%) and dependent cocaine users (34%) exhibited more frequent blue–yellow colour vision
disorders compared to controls (9%). Inferior performance of MDMA users was caused by a subgroup
with high amphetamine co-use (55%), while MDMA use alone was not associated with decreased blue–
yellow discrimination (0%). Cognitive performance was worse in cocaine users with colour vision dis-
order compared to users and controls with intact colour vision and both colour vision impairment and
cognitive deﬁcits were related to cocaine use. Occasional cocaine and amphetamine use might induce
blue–yellow colour vision impairment, whereas the serotonergic stimulant MDMA does not impair colour
vision. The association between colour vision impairment and cognitive deﬁcits in cocaine users may
reﬂect that retinal and cerebral dopamine alterations are linked to a certain degree.
Received 23 January 2012 ; Reviewed 13 April 2012 ; Revised 20 April 2012 ; Accepted 9 May 2012
Key words : Chromatic vision, recreational cocaine use, cognition, memory, lanthony D-15.
Introduction
The psychostimulant cocaine exerts its reinforcing
eﬀect primarily via inhibiting the uptake of dopamine
in the nucleus accumbens and additional structures
of the reward system (Ritz et al. 1987). Numerous
imaging studies with dependent cocaine users have
provided evidence for blunted dopamine neuro-
transmission (Martinez et al. 2004, 2007, 2009, 2011 ;
Volkow et al. 1993, 1997 ; Wu et al. 1997) and ab-
normalities in cerebral glucose metabolism in the
prefrontal cortex (PFC) and further limbic areas
(Bolla et al. 2004; Volkow et al. 1992), leading to wide-
spread motivational, cognitive, behavioural and psy-
chiatric consequences (Bolla et al. 2004). The central
dopamine system holds a pivotal role in the mediation
of PFC function (Braskie et al. 2008; Nieoullon, 2002 ;
Vernaleken et al. 2007), which is crucial for attention,
working memory and executive functions (Benton,
1994). Additionally, it was recently demonstrated that
dopamine neurotransmission is critically involved in
encoding, consolidation and retrieval of declarative
memory (Breitenstein et al. 2006a, b ; Morris et al. 2003;
Whiting et al. 2007, 2008). Consequently, neuro-
psychological impairment has been consistently re-
ported for cocaine-dependent subjects across several
areas of cognitive functioning, including attention and
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executive function, verbal learning and memory
(Fernandez-Serrano et al. 2009; Goldstein et al. 2004;
Kelley et al. 2005; Woicik et al. 2009).
Dopamine also exists in high concentrations in the
retina, where it is localized in the amacrine and inter-
plexiform retinal cells (Bodis-Wollner & Tzelepi, 1998;
Dowling, 1990 ; Witkovsky, 2004). Dopamine acts in
a complex fashion on visual information processing
and is involved in the regulation of lateral inhibition,
centre-surround antagonism and light adaptation,
promoting the light-driven cone input and reducing
the rod input (Brandies & Yehuda, 2008 ; Sannita,
1995 ; Witkovsky, 2004). Moreover, dopamine may
also be involved in chromatic processing by modulat-
ing horizontal cell functioning and the cone-horizontal
cell connectivity (Ahnelt & Kolb, 1994 ; Djamgoz et al.
1997). Indeed, abnormal colour discrimination has
been reported for several neuropsychiatric conditions
featuring altered dopaminergic mechanisms, such as
Parkinson’s and Huntington’s disease, Tourette syn-
drome and attention deﬁcit hyperactivity disorder
(Djamgoz et al. 1997; Melun et al. 2001; Paulus et al.
1993; Pieri et al. 2000; Sartucci et al. 2003; Tannock et al.
2006). These conditions were mainly associated with
speciﬁc colour vision impairment (CVI) along the tri-
tan (blue-hue) axis, which is usually not aﬀected in
congenital CVI. Chronic cocaine use has also been
associated with blue–yellow CVI. Desai et al. (1997)
reported that>48% of dependent cocaine-withdrawn
patients exhibited CVI along the tritan axis in com-
parison to 6.5% of the control subjects. Furthermore,
signiﬁcantly decreased blue cone b-wave electro-
retinogram (ERG) amplitudes were discovered in re-
cently withdrawn cocaine-dependent patients and
lower blue cone b-waves were associated with stron-
ger cocaine craving in these patients (Roy et al. 1996,
1997a). A subsequent longitudinal investigation re-
vealed that the CVI persisted together with cocaine
craving over at least 8 wk (Roy et al. 1997b). The latest
study of Roy et al. (2003) showed that patients with a
reduced blue cone b-wave amplitude exhibited sig-
niﬁcantly lower concentrations of the major dopamine
metabolite homovanillic acid (HVA) in the cerebro-
spinal ﬂuid (CSF). The authors concluded that blue–
yellow CVI in cocaine-dependent subjects reﬂects a
central hypodopaminergic state, as was previously
demonstrated in several molecular imaging studies
(Martinez et al. 2007; Volkow et al. 1990, 1997). How-
ever, it has not been investigated so far if CVI in co-
caine users is correlated with behavioural or cognitive
deﬁcits, which could further indicate a potential
association with frontostriatal dopamine dysfunction
(Backman & Farde, 2001). Prior studies primarily
focused on chronic/dependent cocaine users and it
remains unclear if occasional cocaine users show CVI.
Neither has it been examined if other stimulant drugs
with diﬀerent mechanisms of action, such as MDMA
(commonly known as ‘ecstasy’), also induce CVI. The
substituted amphetamine derivate MDMA mainly
acts on the serotonin system and may ultimately in-
duce serotonergic terminal loss but has not been
shown to cause long-term alterations of the dopamine
system (Capela et al. 2009; Green et al. 2003).
In the present study, we aimed to clarify at which
degree of cocaine exposure CVI occurs and how
speciﬁc it is for cocaine use. Moreover, we investigated
the potential association between CVI and cognitive
alterations in stimulant users. (1) We hypothesized
that colour vision, and in particular blue–yellow
colour vision, is speciﬁcally impaired by the use of
stimulants altering the dopamine system (cocaine and
amphetamine) and not by substances mainly targeting
other neurotransmitter systems such as the serotonin
releaser MDMA. (2) We expected that cocaine-related
CVI would be inﬂuenced by diﬀerent patterns of
cocaine use; therefore, we compared occasional, non-
dependent cocaine users who had used cocaine over
shorter time periods, less frequently and in smaller
doses to dependent cocaine users. (3) We reasoned
that cocaine users with CVI would also exhibit more
pronounced cognitive deﬁcits reﬂecting alterations of
the central dopamine system.
Materials and method
Study design and subjects
The sample consisted of 48 occasional cocaine users,
30 dependent cocaine users, 24 MDMA users and 48
psychostimulant-naive control subjects (total n=150).
Subjects were recruited in Zurich by advertisements
in widely read local newspapers, diﬀerent drug pre-
vention and treatment centres, psychiatric hospitals,
Internet platforms and word-of-mouth communicat-
ion. Inclusion criteria were non-dependent cocaine use
(1–5 g per month, DSM-IV criteria of cocaine depen-
dence not met), dependent cocaine use (o5 g per
month, dependence according to DSM-IV criteria) or
recreational MDMA use (>50 pills/lifetime). Absti-
nence duration of cocaine/MDMA use had to be
<6 months. Participants ’ age had to be between 18
and 65 yr. Exclusion criteria were Axis I or II DSM-IV
psychiatric disorders other than cocaine and alcohol
abuse/dependence, neurological disorders or head
injury, use of opioids or prescription drugs aﬀecting
the central nervous system. Participants had to abstain
from illegal substances for a minimum of 3 d and from
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alcohol for at least 24 h. Urine samples were collected
to ensure abstinence, whereby six occasional and 13
dependent cocaine users tested positive for cocaine.
In order to take eﬀects of acute cocaine use on colour
vision into account, additional analyses were carried
out to determine whether subjects with positive and
negative urine toxicology diﬀered in their colour
vision performance. Several subjects of the control
group had used cannabis. It was decided not to ex-
clude them from the analyses as cocaine and MDMA
users had used cannabis as well. Four subjects (one
from each group) were excluded due to congenital
CVI in the red-green spectrum. The study was ap-
proved by the Cantonal Ethics Committee of Zurich.
Procedure
Neuropsychological and colour vision assessment was
carried out after written informed consent was pro-
vided by all participants. Moreover, a Structured
Clinical Interview for DSM-IV Disorders was carried
out by a trained psychologist. To estimate pre-morbid
verbal intelligence the Mehrfachwahl-Wortschatz-
Intelligenztest (Lehrl, 1999) was applied. Drug use was
assessed by means of the Interview for Psychotropic
Drug Consumption, which has been described in de-
tail in our previous work (Quednow et al. 2004). The
brief version of the Cocaine Craving Questionnaire
(CCQ) was used to assess current cocaine craving
(Sussner et al. 2006; Tiﬀany et al. 1993).
Colour vision assessment and scoring
To assess acquired CVI, the Lanthony Desaturated
Panel D-15 Test (LD-15) was used (Lanthony, 1978).
The test consists of a ﬁxed reference cap and 15
movable colour caps that have to be arranged in con-
secutive order. Colours are of low saturation (de-
creased chroma) and increased lightness. The test was
performed under a daylight ﬂuorescent lamp (GTI
norm daylight, D65, 6500K), providing an illumination
of 1400 lux. Although no time limit was imposed for
test completion, all participants completed the LD-15
within a range of 20 and 560 s (mean=102.50, S.D.¡
72.38). Qualitative scoring is achieved by graphically
scoring the test on a template that describes a hue circle
based on the placement of the caps in the International
Commission on Illumination colour space (Wyszecki
& Stiles, 1982). Single cap inversions (e.g. 1-3-2-4- …)
are classiﬁed as minor errors, whereas cap reversals
spanning two or more positions are considered major
errors. For each individual, diﬀerent colour vision
error-type patterns [protan (red), deutan (green) and
tritan/tetartan (blue–yellow) colour vision deﬁcits]
can be derived by drawing lines between consecutive
caps. Types of acquired dyschromatopsia relied on
Verriest’s classiﬁcation: type I reﬂects CVI along the
red–green axis ; type II is a combined impairment of
the red–green and blue–yellow axis ; type III reﬂects
blue–yellow axis impairment ; type IV is diagnosed
when no clear pattern can be determined. Quantitative
scoring is based on the colour scoring method pro-
posed by Geller (2001), who provided a table that
yields the total colour distance score (TCDS) in the
CIELAB space. A perfect TCDS score of 56.41 results
when all the caps are arranged in consecutive order.
A colour confusion index (CCI) error score can be
calculated by dividing an individual’s actual TCDS
score by the ideal score. A CCI value of 1 constitutes
the perfect score while higher values indicate CVI.
Cognitive assessment
Verbal learning, declarative memory and executive
memory functions were assessed by using a German
version (Helmstaedter et al. 2001) of the Rey Auditory
Verbal Learning Test (RAVLT; Rey, 1964). The RAVLT
was chosen because both cocaine and MDMA users
have been shown to exhibit marked deﬁcits in verbal
learning and declarative memory (Kalechstein et al.
2007; Kelley et al. 2005). The test has been described in
detail elsewhere (Quednow et al. 2006). In brief, the
RAVLT consists of word list A containing 15 nouns
(learning list), a second list B with 15 diﬀerent nouns
(interference list) and a third list C comprising 50
nouns including all words of lists A and B as well as 20
new words that are semantically and phonetically re-
lated (recognition list). As dependent variables were
assessed: working memory span (supraspan, trial 1),
encoding (learning performance, S trials 1–5), recall
consistency in percentage (according to Delis et al.
1987), recall of interference material (list B), recall after
interference (trial 6), long-term memory (delayed re-
call, trial 7 after 30 min), consolidation/retrieval (trial
5 minus 7) and adjusted recognition performance
[p(A), p(B) ; Forrester & Geﬀen, 1991].
Statistical analysis
Statistical analyses were performed with PASW 18.0
(SPSS Inc., USA). Qualitative data were analysed by
means of frequency analyses (Pearson’s x2 test and
Fisher’s exact test where appropriate) and quantitative
data by analyses of variance. For post-hoc analyses,
Sidak corrections were applied. As the assumptions of
homoscedasticity and parametric distribution were
not met by the variables age, years of education, drug
use parameters and colour discrimination data, these
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variables were log-transformed (log 10) and the con-
stant 1 was added because the data contained 0 values.
Log-transformed values are not reported. Because
age, sex and alcohol/nicotine consumption were
shown to have an impact on colour vision (Erb et al.
1999; Jackson & Owsley, 2003 ; Mergler et al. 1988;
Rodriguez-Carmona et al. 2008), and years of edu-
cation diﬀered between groups, these parameters
were introduced as covariates in analyses of covari-
ance (ANCOVA) of the CCI. Age and years of edu-
cation were introduced as covariates in ANCOVAs of
memory performance. Correlation analyses (Pearson’s
product-moment) and binary logistic regression
analyses were conducted to relate drug use para-
meters to deﬁcits in colour discrimination and cogni-
tive performance. Sensitivity and speciﬁcity of the
LD-15 were calculated according to Cooper et al.
(1979) and ICCVAM (1997). Eﬀect sizes were cal-
culated with G*Power 3.1 (Faul et al. 2007).
Results
Demographic variables and drug use
Information regarding demography and verbal IQ are
displayed in Table 1. Groups did not diﬀer in sex
distribution, verbal IQ and smoking status, whereas
there were signiﬁcant diﬀerences in age and years of
education. Dependent cocaine users were signiﬁcantly
older (p<0.001) and had fewer years of education
(p<0.01–0.001) than participants from all other groups.
However, MDMA users, occasional cocaine users
and controls were well matched among all variables.
Age and years of education were still introduced as
covariates in all analyses.
The drug use pattern of all groups is shown in
Table 2. Dependent cocaine users smoked signiﬁcantly
more cigarettes per week than controls (F3,142=4.24,
p<0.01 ; post-hoc p<0.01) and both occasional and
dependent cocaine users consumed more alcohol
(g/wk) than MDMA users (F3,142=4.031, p<0.01 ;
post-hoc p<0.01, p<0.05) but not in comparison to
controls.
Qualitative analyses of the LD-15
Qualitative analyses revealed a signiﬁcant group
eﬀect regarding the presence of blue–yellow and total
CVI impairment (Table 1, Fig. 1). CVI was more fre-
quent in both, occasional [x21=9.73, p<0.01, odds ratio
(OR) 5.21) and dependent cocaine users (x21=13.55,
p<0.001, OR=7.84), but not in MDMA users (Fisher’s
exact p=0.159), when compared to control subjects
(Fig. 1). Occasional and dependent cocaine users did
not diﬀer from each other. The most frequent type of
CVI was along the blue–yellow axis (type III disorder),
where occasional (x21=6.87, p<0.01, OR 4.56) and de-
pendent cocaine users (x21=8.05, p<0.01, OR 5.66)
showed signiﬁcantly more frequent blue–yellow CVI
than controls (Fig. 1). A tendency that MDMA users
exhibited type III disorder more frequently than con-
trols was found (Fisher’s exact p=0.07). Once again,
occasional and dependent cocaine users did not sig-
niﬁcantly diﬀer from one another in the frequency of
type III disorders. Although there was no statistically
signiﬁcant diﬀerence between the groups regarding
the frequency of type II disorders, occasional and de-
pendent cocaine users showed more frequent red–
green CVI than controls and MDMA users.
Approximately half of the subjects in the MDMA
group indicated that they also used amphetamine
on a regular basis. Interestingly, when the MDMA
group was divided into a ‘ low’ (<150 g amphetamine
lifetime, mean¡S.D.=52.8¡48.6 g, n=12) and ‘high’
amphetamine user group (>150 g lifetime, mean¡
S.D.=371¡307 g, n=11), none of the low amphet-
amine MDMA users suﬀered from blue–yellow CVI,
whereas in the high amphetamine MDMA group
55% showed blue–yellow CVI (Fisher’s exact p<0.05,
W=x0.429).
Quantitative analyses
Quantitative analyses showed that the CCI diﬀered
signiﬁcantly between groups (Table 1), even after
controlling for age, sex, alcohol consumption, smoking
and years of education (F3,137=3.72, p<0.05, g2=0.08).
Post-hoc analyses indicated that the CCI of occasional
(p<0.05, d=0.60) and dependent cocaine users (p<
0.05, d=0.73) was signiﬁcantly higher than the CCI
of controls. In addition, dependent cocaine users
also showed signiﬁcantly higher CCI scores in com-
parison to MDMA users (p<0.05). Occasional and
dependent cocaine users did not diﬀer from one
another. None of the covariates were signiﬁcantly re-
lated to the CCI.
Conﬁrming the results obtained in the qualitative
analysis, high amphetamine MDMA users (CCI 1.25¡
0.17) showed signiﬁcantly inferior colour discrimi-
nation performance compared to low amphetamine
MDMA users (CCI 1.07¡0.08 ; post-hoc p<0.01 ;
d=1.21) and controls (CCI 1.09¡0.14, p<0.01; d=1.10),
while low amphetamine users and controls did not
diﬀer (overall all groups, F2,67=6.91, p<0.01, g2=0.17).
To investigate the impact of cannabis use across
all four groups, an ANCOVA (covariates see above)
with cannabis use (yes/no) and group as ﬁxed-factors
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Table 1. Demographic data and colour vision impairment types, CCI and TCDS
Stimulant-naive
controls (n=47)
Occasional MDMA
users (n=23)
Occasional cocaine
users (n=47)
Dependent cocaine
users (n=29) F/x2/t df/dferr. p
Eﬀect
size
Age 26.85 (6.95) 23.22 (5.37) 27.21 (7.14) 35.90 (10.86) 13.47a 3/142 <0.001 0.22e
Sex (m/f) 39/8 (83%, 17%) 22/1 (96%, 4%) 39/8 (83%, 17%) 22/7 (76%, 24%) 3.81b 3 0.29
Years of education 11.55 (1.46) 11.26 (1.74) 10.96 (1.68) 9.50 (1.15) 11.45a 3/142 <0.001 0.20e
Verbal IQ (MWT-B) 107.06 (10.35) 101.43 (11.02) 104.11 (11.14) 103.10 (11.82) 1.62a 3/142 0.19
Smokers/non-smokers 35/12 (75%, 25%) 19/4 (83%, 17%) 40/7 (85%, 15%) 27/2 (93%, 7%) 4.47b 3 0.20
Cocaine craving (CCQ) – – 18.64 (9.29) 19.52 (9.12) x0.39d 69 0.70
Colour vision impairment
Type I 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1.00c 3 1.000
Type II 1 (2%) 0 (0%) 4 (9%) 3 (10%) 4.51c 3 0.211 0.18f
Type III 4 (9%) 6 (26%) 14 (30%) 10 (35%) 8.99c 3 0.029 0.25f
Type IV 0 (0%) 0 (0%) 0 (0%) 1 (3%) 4.06c 3 0.255 0.17f
Total 5 (11%) 6 (26%) 18 (38%) 14 (48%) 14.85c 3 0.002 0.32f
CCI 1.09 (0.14) 1.16 (0.16) 1.30 (0.33) 1.40 (0.49) 8.00a 3/142 <0.001 0.14e
CCI (range) 1.00–1.60 1.00–1.64 1.00–2.31 1.00–3.36
TCDS 61.67 (7.84) 65.14 (9.05) 73.15 (18.81) 79.09 (27.74) 8.19a 3/142 <0.001 0.15e
CCI, Colour confusion index ; TCDS, total colour distance score ; MDMA, commonly known as ‘ecstasy’ ; df/dferr, degrees of freedom/degrees of freedom for errors ;
MWT-B, Mehrfachwahl-Wortschatz-Intelligenztest ; CCQ, Cocaine Craving Questionnaire.
a ANOVA (over all groups).
b Fisher’s exact test (over all groups).
c x2-test for frequency data.
d Independent t test (cocaine users only).
e g2.
f Cramer’s V, type I=red–green ; type II=red–green and blue–yellow; type III=blue–yellow; type IV=no clear pattern.
Values are means and S.D. in parentheses, number of subjects and percentage.
Signiﬁcant p values (p<0.05) are shown in bold.
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was calculated. Neither the factor cannabis use nor
the grouprcannabis use interaction was signiﬁcant
(F<1.0), whereas the group eﬀect remained un-
changed (F3,133=2.94, p<0.05, g2=0.06). Given that
19 cocaine users were tested positive for cocaine in
urine screening, we investigated the eﬀect of acute
cocaine eﬀects on the CCI within cocaine users.
In an ANCOVA (covariates see above) with group
(occasional/dependent users) and urine test (positive/
negative) as ﬁxed-factors, both main eﬀects were not
signiﬁcant (F<0.20). However, a disordinal groupr
urine test interaction was found (F1,67=4.12, p<0.05,
g2=0.06), indicating that positive tested occasional
cocaine users exhibited more pronounced CVI than
negative tested occasional users, whereas positive
tested dependent users displayed less CVI than nega-
tive tested dependent users (Fig. 2).
Sensitivity and speciﬁcity of the LD-15
Sensitivity calculations indicated that the LD-15
correctly identiﬁed CVI (all types) in cocaine users in
42% of the cases. Speciﬁcity was 84%, indicating a
false-positive rate of 16% for the controls and MDMA
users. The positive predictive value (PPV) or, in other
words, the probability that an individual actually ex-
hibits CVI when a positive test result was observed
was 74%. The negative predictive value (NPV) or the
probability that an individual without CVI really is
free from the condition was 57%. Sensitivity for
Table 2. Drug use parameters
Stimulant-naive
controls (n=47)
Occasional MDMA
users (n=23)
Occasional cocaine
users (n=47)
Dependent cocaine
users (n=29)
Nicotine
Cigarettes/wk 59.33 (65.30) 74.83 (58.46) 83.18 (60.63) 122.64 (97.85)
Years of use 5.78 (7.39) 4.63 (3.23) 7.93 (6.11) 17.81 (11.16)
Alcohol
g/wk 115.68 (137.18) 94.18 (106.74) 173.81 (154.12) 281.98 (382.02)
Cocaine
g/wk – 0.18 (0.55) 1.01 (1.08) 5.46 (6.77)
Years of use – 0.52 (1.09) 4.58 (3.70) 12.32 (7.39)
Cumulative dose (g) – 17.95 (47.50) 330.75 (470.01) 6495.38 (9148.92)
Last use (d) – 34.00 (17.72) n=5 26.29 (34.33) 18.95 (34.58)
Amphetamine
g/wk – 0.77 (1.27) 0.07 (0.24) 0.00 (0.01)
Years of use – 2.71 (2.02) 1.20 (2.66) 1.28 (4.18)
Cumulative dose (g) – 204.41 (264.83) 43.73 (127.13) 15.75 (61.85)
Last use (d) – 86.33 (180.70) n=18 172.61 (242.65) n=20 81.63 (81.42) n=4
MDMA
Pills/wk – 1.65 (2.69) 0.03 (0.12) 0.05 (0.12)
Years of use – 2.79 (2.01) 1.38 (3.49) 2.57 (5.15)
Cumulative dose (pills) – 442.36 (469.72) 37.88 (116.45) 235.42 (751.43)
Last use (d) – 60.95 (157.25) 227.20 (280.00) n=14 72.48 (52.01) n=8
Cannabis
g/wk 0.31 (0.73) 3.79 (4.55) 2.62 (5.95) 2.25 (5.66)
Years of use 3.15 (5.03) 3.76 (3.11) 6.19 (5.59) 9.63 (11.45)
Cumulative dose (g) 791.80 (4001.99) 1015.24 (1307.18) 1601.37 (3680.61) 4260.99 (8694.76)
Last use (d) 29.70 (44.94) n=20 15.60 (26.69) n=15 17.62 (28.99) n=35 19.87 (25.12) n=16
Hallucinogens
Cumulative dose (times) 4.75 (3.37) n=8 27.25 (40.97) n=16 29.83 (65.48) n=23 16.10 (23.14) n=15
Last use (months) 38.50 (43.25) n=8 6.31 (7.29) n=16 40.07 (47.23) n=23 112.60 (135.42) n=15
MDMA, Commonly known as ‘ecstasy’.
Use per week, duration of use and cumulative dose are averaged within the total group. Last use is averaged only for subjects
who used the drug. In this case, sample size is shown.
Values are means (S.D.).
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blue–yellow CVI was 32%, speciﬁcity 91%, PPV 71%
and NPV 54%.
Verbal learning and declarative memory performance
To investigate the association of CVI and memory per-
formance, cocaine users with diagnosed CVI (CocCVI),
cocaine users without CVI (Cocnon-CVI) and controls
without CVI were compared (Table 3). ANCOVA
analyses were corrected for age and years of edu-
cation. Importantly, CocCVI and Cocnon-CVI did not
signiﬁcantly diﬀer regarding cocaine use parameters.
In general, cocaine users showed worse performance
in the working memory span, recall after interference
and delayed recall, when compared to controls.
Moreover, CocCVI showed inferior performance com-
pared to Cocnon-CVI in the supraspan, learning, recall
consistency, delayed recall and recognition of lists A
and B. Controls diﬀered from CocCVI in all memory
parameters.
In a second step, we investigated whether RAVLT
performance scores were correlated with CCI sores
and cocaine use (Table 4). Control subjects were
excluded from this analysis in order to prevent in-
ﬂation of existing associations and MDMA users
because previous ﬁndings have shown that MDMA
users exhibit marked verbal declarative memory deﬁ-
cits (Quednow et al. 2006). After controlling for age,
the CCI correlated negatively with the supraspan,
learning performance, delayed recall, adjusted recog-
nition for list A, and positively with loss after con-
solidation, reﬂecting that more pronounced CVI was
associated with worse memory performance. When
corrected for age, cocaine use, particularly lifetime
use, was correlated with several memory parameters
(Table 4), indicating worse memory performance with
increasing cocaine use. Last cocaine use (d) was not
signiﬁcantly related to any of the RAVLT variables
(data not shown).
Association between CVI, substance use and
demographic data
In the total sample, CCI sores were correlated with age
(r=0.21, p<0.05), years of education (r=x0.19,
p<0.05), cigarettes smoked per week (r=0.17, p<0.05)
and years of smoking (r=0.22, p<0.01), indicating
worse colour discrimination with increasing age,
lower education and higher nicotine use. Alcohol and
cannabis use, sex and verbal IQ were not associated
with the CCI.
For the correlations between illegal drug use and
the CCI (except for cannabis), control subjects were
excluded to prevent inﬂating existing correlations.
Alcohol, cannabis, amphetamine andMDMAusewere
not associated with the CCI. Only cocaine use (yr :
r=0.25, p<0.05, n=99) and cocaine lifetime use (g;
r=0.25, p<0.05, n=99) were positively correlated
with the CCI. The eﬀects remained after adjusting for
age (both r=0.20, p<0.05). A binary logistic regression
analysis (stepwise forward) examining the association
of age, verbal IQ, years of education, cigarettes per
week, alcohol use (g/wk), lifetime use of cannabis,
amphetamine, cocaine (g) and MDMA (pills), with
CVI indicated that the presence of dyschromatopsia
was only related to cocaine lifetime use (b=0.36,
p<0.05), whereas no signiﬁcant associations were
found with any other variables.
Cocaine craving (CCQ) was not signiﬁcantly
correlated with the CCI. Furthermore, CocCVI and
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Fig. 1. Frequency of blue–yellow colour vision impairment
(CVI) and all types of CVI (%) for stimulant-naive controls,
occasional MDMA (commonly known as ‘ecstasy’) users,
occasional cocaine users and dependent cocaine users.
** x2-test : p<0.01 ; *** x2-test : p<0.001.
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Fig. 2. Signiﬁcant interaction between cocaine group
(47 occasional vs. 29 dependent users) and urine toxicology
(UT; 19 positive vs. 57 negative tests) (F1,67=4.12, p<0.05).
Means and S.E.M. are shown.
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Cocnon-CVI did not signiﬁcantly diﬀer in their CCQ
scores (data not shown).
Discussion
Occasional and dependent cocaine users both showed
more frequent and more intense CVI, predominantly
in the blue–yellow spectrum, in comparison to psy-
chostimulant-naive controls. CVI in dependent co-
caine users was more pronounced than in occasional
cocaine users, as indicated by the larger eﬀect sizes
and the higher prevalence of CVI in the qualitative
data. However, it is noteworthy that CVI was already
highly frequent in occasional cocaine users. MDMA
Table 3. Verbal learning/memory performance of controls without CVI and cocaine users with and without CVI
RAVLT parameters Con (n=42)
Cocaine users
without CVI
(n=44)
Cocaine users
with CVI
(n=32) F df/dferr. p
Sidak post-hoc group
comparisons (p<0.05)
Working memory span
(trial 1)
9.58 (1.95) 8.67 (1.86) 8.13 (1.91) 4.91 2/113 <0.01 Con>Cocnon-CVI>CocCVI
Learning performance
(trials S1–5)
63.42 (7.45) 60.21 (7.08) 55.38 (7.27) 10.12 2/113 <0.001 Con, Cocnon-CVI>CocCVI
Recall consistency,
trials 1–5 (in percent)
92.67 (9.75) 90.04 (9.27) 84.71 (9.51) 5.95 2/113 <0.01 Con, Cocnon-CVI>CocCVI
Interference trial (list B) 8.97 (2.42) 8.29 (2.30) 7.36 (2.36) 3.88 2/113 <0.01 Con>CocCVI
Recall after interference
(trial 6)
13.44 (2.37) 12.14 (2.26) 11.25 (2.31) 7.54 2/113 <0.01 Con>Cocnon-CVI, CocCVI
Delayed recall
(trial 7 after 30 min)
13.55 (2.11) 12.53 (2.00) 11.27 (2.06) 10.03 2/113 <0.001 Con>Cocnon-CVI>CocCVI
Loss after consolidation
(trial 5 minus 7)
0.65 (1.47) 1.13 (1.40) 1.65 (1.44) 3.98 2/113 <0.01 Con>CocCVI
Adjusted recognition
list A [p(A) list A]
0.90 (0.11) 0.87 (0.11) 0.82 (0.11) 4.98 2/113 <0.01 Con, Cocnon-CVI>CocCVI
Adjusted recognition
list B [p(A) list B]
0.82 (0.13) 0.77 (0.12) 0.70 (0.12) 6.73 2/113 <0.01 Con, Cocnon-CVI>CocCVI
CVI, Colour vision impairment ; RAVLT, Rey Auditory Verbal Learning Test ; Con, stimulant naive controls without CVI ;
df/dferr ; CocCVI, cocaine users with CVI ; Cocnon-CVI, cocaine users without CVI.
Values are means adjusted for age and years of education (S.D.).
Table 4. Correlations between memory performance, CCI and cocaine use parameters in cocaine users
CCI Cocaine (g/wk)
Cocaine
(years of use)
Cocaine
(lifetime in g)
Cocaine
(max. in g/d)
Supraspan x0.27 (0.02) x0.22 (0.06) x0.36 (0.001) x0.39 (0.004)
Learning performance (trials g1–5) x0.33 (0.004) x0.26 (0.02) x0.25 (0.03) x0.38 (0.001) x0.33 (0.006)
Recall consistency, trials 1–5 (in %) x0.20 (0.09) x0.23 (0.06) x0.30 (0.01) x0.22 (0.06)
Interference trial (list B) x0.19 (0.10) x0.21 (0.07) x0.20 (0.09)
Recall after interference (trial 6) x0.19 (0.10) x0.34 (0.003) x0.29 (0.01) x0.33 (0.004) x0.27 (0.03)
Delayed recall (trial 7 after 30 min) x0.27 (0.02) x0.21 (0.07) x0.20 (0.09) x0.31 (0.008)
Loss after consolidation (trial 5 minus 7) 0.24 (0.04)
Adjusted recognition list A [p(A) list A] x0.26 (0.02) x0.30 (0.008) x0.33 (0.004) x0.28 (0.02)
Adjusted recognition list B [p(A) list B] x0.22 (0.06) x0.22 (0.06) x0.22 (0.06) x0.39 (0.001) x0.36 (0.002)
CCI, Colour confusion index.
Correlations are adjusted for age. Correlations with a p level<10% are shown, while signiﬁcant correlations (p<0.05) are shown
in bold.
Partial correlation r with p values shown in parentheses.
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users with low exposure to dopaminergic stimulants
did not show changes in colour vision but MDMA
users who had often used amphetamine showed simi-
lar blue–yellow CVI as cocaine users. Higher CCI was
related to higher cumulative lifetime cocaine use and
longer duration of use. Moreover, the presence of CVI
was clearly associated with diminished verbal declara-
tive memory performance in cocaine users, possibly
reﬂecting a potential relationship between retinal and
cerebral dopaminergic alterations. Overall, these re-
sults support the notion that CVI, particularly blue–
yellow CVI, is speciﬁc for drugs mainly altering the
dopamine system, such as cocaine and amphetamine.
The present ﬁndings are largely consistent with
previous studies providing evidence that blue–yellow
CVI prevails in withdrawn cocaine-dependent pa-
tients (Desai et al. 1997; Roy et al. 1996, 1997a, b, 2003).
However, our report elaborated on this ﬁnding by
showing that occasional cocaine and amphetamine
use was associated with blue–yellow CVI and that a
diﬀerent pattern applies for occasional stimulant
use regarding abstinence. The authors of prior studies
proposed that the CVI was due to the eﬀect of cocaine
on dopaminergic retinal neurotransmission leading
to a hypodopaminergic state and not owing to the
eﬀect of cocaine on ocular blood vessels, as a careful
examination indicated no retinal lesions. Compared to
Desai et al. (1997), who reported that 48% of the de-
pendent cocaine users exhibited blue–yellow CVI, a
lower prevalence of 35% for dependent and 30% for
occasional cocaine users was found in the present
sample. However, this may be due to slightly diﬀerent
error classiﬁcations between both studies, as we found
that 48% of the dependent and 38% of the occasional
cocaine users showed CVI when all types of CVI were
considered. Furthermore, in our study, 19 of 76 users
tested positive for cocaine in urine toxicology and may
not have been suﬀering from an acute hypodopa-
minergic state. In accordance with Desai et al. (1997),
no signiﬁcant correlation between CVI and days of
cocaine abstinence was found in the present results.
Moreover, Roy et al. (1996, 1997a) found that cocaine-
dependent patients with an ERG blue cone b-wave
amplitude <0.5 mV reported stronger cocaine crav-
ing, which is in line with the ﬁnding that reduced
D2 receptor binding in the dorsal striatum during a
cocaine-cue condition was linked to self-reports
of cocaine craving (Volkow et al. 2006). In contrast,
cocaine users with CVI in the present sample did not
report stronger cocaine craving than cocaine users
without CVI. Given that Roy et al. (1996, 1997a, b) had
used the 45-item version of the CCQ, diﬀerences in the
magnitude of the reported craving scores cannot be
directly compared. Nevertheless, cocaine users from
the present study may have experienced less craving,
as several users had tested positive for cocaine in the
urine analysis.
Earlier studies have not examined the relationship
between CVI and drug use patterns in detail. In the
present report, CVI was correlated with lifetime
quantity and duration of cocaine use, supporting the
view that CVI might be cocaine-induced. However,
the cross-sectional design of the study does not allow
a ﬁnal conclusion regarding causality. Even though
dependent cocaine users were more strongly impaired
in colour vision discrimination than occasional cocaine
users, the relatively small diﬀerence between the two
groups raises the question as to whether a hypodopa-
minergic state could be a pre-morbid trait that func-
tions as a risk factor or possibly that CVI may be due to
a predispositionrsubstance-induced eﬀects interac-
tion. Although abstinence period since last cocaine use
was not directly related to LD-15 performance, it is
noteworthy that occasional cocaine users showed bet-
ter colour discrimination when the urine toxicology
tested negative for recent cocaine use, while depen-
dent cocaine users performed better when they
were tested positive. A potential explanation could be
that the hypodopaminergic state was less severe
in occasional cocaine users ; therefore, acute dopamine
release had no beneﬁcial eﬀect on their colour dis-
crimination ability. Furthermore, neither alcohol nor
any of the other psychoactive drugs were signiﬁcantly
related to CVI in cocaine users. Finally, it was not
possible to identify a threshold value as to after which
cocaine doses CVI occurs. However, for both oc-
casional and dependent cocaine users, duration and
quantity of cocaine use were most strongly related
to CVI.
MDMA users who had co-used amphetamine
showedblue–yellowCVI,whileMDMAuserswhohad
used little amphetamine did not exhibit blue–yellow
CVI. The correlation between CVI and amphetamine
use was not signiﬁcant, but only a few subjects re-
ported amphetamine use and thus the power to detect
a dose–response relationships was low. Although
some animal studies have yielded evidence that
MDMA, at least acutely and in a much less potent
manner than amphetamine-like derivates (Partilla et
al. 2006), also increases synaptic dopamine levels and
dopamine eﬄux (Baumann et al. 2007; Yamamoto &
Bankson, 2005), the majority of the studies only re-
ported selective neurotoxicity for 5-HT-containing
neurons (for review, see Capela et al. 2009). It is
currently controversial if cocaine use can also be neuro-
toxic for dopaminergic neurons ; however, recent
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human post-mortem studies support this notion (Little
et al. 2009; Okvist et al. 2011).
We have demonstrated that CVI was associated
with working memory span, encoding and retrieval
deﬁcits in cocaine users. In line with the present re-
sults, several measures of verbal memory, attentional
performance and executive function have consistently
revealed deﬁcits in withdrawn cocaine users
(Fernandez-Serrano et al. 2009; Goldstein et al. 2004;
Kelley et al. 2005; Woicik et al. 2009). Many cognitive
processes, working memory and executive functions,
in particular, are mediated by the PFC, which is
strongly dependent on intact dopamine signalling
(Braskie et al. 2008; Nieoullon, 2002 ; Vernaleken et al.
2007). Accordingly, cocaine users with CVI displayed
worse performance in memory parameters previously
associated with the PFC, such as working memory
span and recall consistency (Quednow et al. 2006).
Given that cocaine use may exert its inﬂuence on both
cognition and colour vision, a possible link between
alterations in the frontostriatal and retinal dopamine
system is self-evident. Prior studies have indeed
provided evidence pointing in this direction. As men-
tioned above, decreased blue cone b-wave ERG am-
plitudes in dependent cocaine users were associated
with lower concentrations of CSF HVA (Roy et al.
2003), and reduced striatal D2 receptor availability was
related to lower metabolic activity in the medial PFC
and the anterior cingulate gyrus persisting 3–5 months
after detoxiﬁcation (Volkow & Li, 2004 ; Volkow et al.
1988, 1991, 1993). However, the speciﬁc mechanism
of how dopamine mediates colour vision discrimi-
nation remains elusive and it is unclear how stimulant
use precisely aﬀects retinal dopamine transmission.
Naturally, the question arises as to what extent
alterations in the frontostriatal and retinal dopamine
system may be linked. Combining cerebral molecular
imaging with ophthalmological/electrophysiological
methods could greatly contribute to a better under-
standing of the exact mechanism by which blue–
yellow CVI and cognitive dysfunction occur. In some
studies, it was postulated that short wavelength-
sensitive cones (blue cones) may generally be more
vulnerable to toxic noxa and ageing than medium and
long wavelength-sensitive cones, possibly due to their
relative scarcity and anatomical distribution (Djamgoz
et al. 1997; Hart, 1987 ; Masson et al. 1993; Witkovsky,
2004). Moreover, mammalian studies report that cer-
tain cell types in the retina have selective blue-cone
input that is mediated by dopamine transmission
(Djamgoz et al. 1997).
Eventually, the usefulness of the LD-15 as a marker
for dopaminergic and cognitive alterations shall be
addressed. The present results imply that although the
speciﬁcity of the LD-15 was good, its sensitivity is not
high enough for diagnostic and predictive purposes
regarding blue–yellow CVI in cocaine users. Roy et al.
(1997a, b, 2003) have previously suggested that ERG
blue cone b-wave amplitudes may serve as a neuro-
biological marker related to central dopamine function
in cocaine-dependent patients. It would be of interest
to further investigate the correspondence between
ERG blue cone amplitudes and the LD-15 and cogni-
tive deﬁcits.
Some limitations inherent to the investigation of
CVI were present in this study. Colour vision is inﬂu-
enced by several factors besides stimulant use, such as
age, alcohol and nicotine use. However, occasional
cocaine users, MDMA users and controls were well
matched and potentially confounding variables were
controlled in the analyses. The sensitivity of the LD-15
is limited and blue–yellow CVI also occurred in con-
trols, although to a much lower extent. Furthermore,
the possibility that some cocaine users may have suf-
fered minor ocular blood vessel bursts cannot be ruled
out since participants did not undergo an ophthalmo-
logical examination. Nevertheless, results from prior
studies controlling for blood vessel damage are con-
sistent with the ﬁndings of the current study (Desai
et al. 1997; Roy et al. 1996). Moreover, in addition to
alterations in dopaminergic transmission in the retina,
sub-cortical and cortical processing may also be aﬀec-
ted and contribute to decreased colour discrimination
ability (Conway et al. 2010). Finally, the history of drug
consumption was assessed only by means of self-
reports, precluding the calculation of lifetime drug use
objectively (Curran, 2000).
Conclusion
In conclusion, this study provided evidence that drug
users consuming stimulants that mainly alter the
dopaminergic neurotransmitter system exhibit more
frequent blue–yellow CVI and that stimulant users
with an occasional cocaine use pattern are aﬀected to a
similar extent as chronic users. Furthermore, CVI was
found to be associated with decreased performance
in verbal learning and memory in occasional and
dependent cocaine users, implying that retinal and
cerebral dopaminergic alterations could be linked to a
certain degree.
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